Silexion Therapeutics Corp (SLXNW)

The immediate outlook is severely compromised by a catastrophic balance sheet. The company carries a debt-to-equity ratio exceeding 3,200, indicating that liabilities dwarf equity, while operating cash flow is deeply negative at -$12.4 million annually. This liquidity crisis is compounded by a current ratio below 1.0, meaning the firm cannot cover its short-term obligations with available assets. Although the recent news of a business combination with Moringa Acquisition Corp offers a potential path to survival, the underlying financial structure remains fragile without verified post-merger capitalization details. Consequently, the short-term rating is assigned a low 0.5, reflecting a high probability of further distress or dilution rather than a clear recovery play. On a long-term basis, the security is rated a dismal 0.5 due to the absence of any multi-year price history to validate business quality, combined with the fundamental risks of insolvency and the speculative nature of SPAC mergers. There is no dividend capability given the lack of earnings and cash generation.